Cargando…
Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
The enhancer of zeste homolog 2 (EZH2) is the enzymatic subunit of the polycomb repressive complex 2 (PRC2) that exerts important functions during normal development as well as disease. PRC2 through EZH2 tri-methylates histone H3 lysine tail residue 27 (H3K27me3), a modification associated with repr...
Autores principales: | Alzrigat, Mohammad, Jernberg-Wiklund, Helena, Licht, Jonathan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370027/ https://www.ncbi.nlm.nih.gov/pubmed/30761216 http://dx.doi.org/10.3390/epigenomes2030016 |
Ejemplares similares
-
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma
por: Alzrigat, Mohammad, et al.
Publicado: (2017) -
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
por: Alzrigat, Mohammad, et al.
Publicado: (2016) -
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
por: Alzrigat, Mohammad, et al.
Publicado: (2017) -
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
por: Agarwal, Prasoon, et al.
Publicado: (2016) -
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
por: Nylund, Patrick, et al.
Publicado: (2021)